Aspen Pharmacare Holdings Limited (“Aspen”), listed on the JSE, South Africa (share code APN) and Strides Arcolab Limited, today announced a restructuring of their arrangements relating to the two oncology joint ventures (“JVs”) between Aspen and Strides, Onco Therapies Limited (“OTL”), India and Onco Laboratories Limited (“OLL”), Cyprus. The transactions The following are the material… Continue reading Aspen and Strides restructure Oncology arrangements
Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong returns for the six months ended 31 December 2009. The excellent performance from the South Africa business underpinned the results. Group Performance: Group revenue increased by 10 percent to R4.576 billion (R4.142 billion). Group operating profit increased by 16 percent to R1.314… Continue reading Aspen raises profits by 31% as South African business shines
Johannesburg – Eli Lilly today announced the US$1 million milestone payment to Aspen, South Africa’s leading pharmaceutical manufacturer, as part of the joint collaboration on expanding access to medicines to treat multidrug-resistant tuberculosis (MDR-TB). The milestone is part of a Transfer of Technology agreement between Aspen and Lilly, initiated in 2003 under the umbrella of… Continue reading Aspen Receives US $1 Million In Transfer of Technology Agreement
Johannesburg – JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, has produced excellent results for the year ended 30 June 2009. Prevailing global economic conditions did little to deter the strength of the Group’s performance, with the South African and Australian businesses continuing to perform well. Aspen’s international expansions resulted in substantially increased… Continue reading Aspen’s revenue increases by 80 percent as international business expands
A message from Aspen Group Chief Executive, Stephen Saad, to the mothers of South Africa’s babies: “At Aspen we understand that the wellbeing of your baby is of utmost importance. I confidently give you my assurance that Aspen’s S26 infant milk formula available to you in South Africa is of the highest quality. My confidence is… Continue reading Aspen’s S26 Assurance of Quality
Johannesburg: Aspen Nutritionals, manufacturer of S-26 and other infant milk formulations (IMFs), confirms that all IMFs manufactured and marketed by Aspen Nutritionals are safe for infant consumption. This statement is being issued in response to a media report concerning the Tanzanian Food and Drug Administration’s withdrawal notification of a consignment of S-26, which, until proven… Continue reading Quality of S-26 in South Africa Guaranteed
OFFICIAL STATEMENT REGARDING THE ALLEGED PURCHASE TRANSACTIONS ENTERED INTO BETWEEN ASPEN AND FRANKEL CHEMICALS FOR THE PURCHASE BY ASPEN FROM FRANKEL CHEMICALS OF RAW MATERIALS FOR THE MANUFACTURE OF ANTI-RETROVIALS. ASPEN PHARMACARE HOLDINGS LIMITED AND ITS AFFILIATES (“Aspen”) AND FRANKEL CHEMICALS (“Frankel”) It has come to the attention of Aspen that information allegedly pertaining to… Continue reading Official statement regarding the alleged purchase transactions entered into between Aspen and Frankel Chemicals
Press Conference Presentation <Click to download> SENS Announcement <Click to download> The Transactions comprise: The acquisition of the rights to distribute GSK products in South Africa by Aspen’s wholly owned subsidiary, Pharmacare Limited (“the SA Component”); The formation of a collaboration arrangement in relation to the marketing and selling of prescription pharmaceutical products in sub-Saharan… Continue reading Aspen and GSK agree on Strategic Deals
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
